



## Curriculum Vitae

Personal information **Karin Janssen van Doorn**

### Work experience

1. Freelance Medical Expert Juridical Court and Funding for Medical Accidents (Belgium). Start date 092024
2. Employer: FAMHP
  - Start date: 072015
  - End date:
  - Position: Clinical assessor - SAWP/CHMP/RIWP representative
  - Activities:
  - Country: Belgium
3. Employer: UZA Antwerp
  - Start date: 092008
  - End date: 082014
  - Position: Staff member
  - Activities: Nephrology, Hemodialysis, Peritoneal dialysis, Renal transplantation, stem cell apheresis, Acute Kidney Injury (ICU),
  - Country: Belgium

### Education and training

1. Subject: Free University of Brussels
  - Start date: 091989
  - End date: 061996
  - Qualification: MD
  - Organisation: Medicine
  - Country: Belgium
2. Subject: Free University of Brussels
  - Start date: 092003
  - End date: 062006
  - Qualification: Master
  - Organisation: Ethics
  - Country: Belgium
3. Subject: University Antwerp and Brussels
  - Start date:
  - End date:
  - Qualification: PhD in Medical Sciences
  - Organisation: OBSERVATIONAL STUDIES ON RENAL IMPAIRMENT IN CRITICALLY ILL PATIENTS 3/2016
  - Country: Belgium
4. Subject: Free University of Brussels
  - Start date: 092019
  - End date: 122019
  - Qualification: Post Master Course Introduction Medical Law.
  - Organisation: Faculty Law and Criminology
  - Country: Belgium
5. Subject: University of Ghent. Start date: 011022. End date: 300623. Qualification: Introduction to Law for Court Experts. Organisation: Faculty law and Criminology. Country: Belgium

### Additional information

#### Publications

1.K. Janssen van Doorn, E. Debing, F. Van Tussenbroeck, A. Goossens, P. Van den Brande and P. Van der Niepen. Unilateral hydronephrosis and recurrent endometrial stromal sarcoma with review of the literature. Acta Clin Belg 1999; 54(3): 165\_168. 2.K. Janssen van Doorn, P. Van der Niepen, F. Van Tussenbroeck and D. Verbeelen. Acute tubulo\_interstitial nephritis and renal infarction secondary to ergotamine therapy. Nephrol Dial Transpl 2000; 15: 1877\_1879. 3.K. Janssen van Doorn, M. Diltoer, S. Servotte, K. Jochmans, M. Laubach, M. Keuppens and L. Huyghens. Transfusion of polymerized bovine haemoglobin in a patient with sickle cell anemia and severe allo\_immunization: a case report. Acta Clin Belg 2001; 56(3): 191\_194. 4.K. Janssen van Doorn, B. Neyns, P. Van der Niepen and D. Verbeelen. Pamidronate related nephrotoxicity (tubulo\_interstitial nephritis) in a patient with osteolytic bone metastases. Nephron: 2001; 89: 467\_468. 5.P. Van der Niepen, K. Janssen van Doorn, K. Van den Houte, D. Verbeelen. Crystalline nephropathy reviewed acute renal failure and nimesulide. Nephrol Dial Transpl 2002; 17: 315\_316. 6.K. Janssen van Doorn, D. Pierard, D. Verbeelen. Typhoid Fever: Letter to the editor. N Engl J Med 2003;348(12):1182\_1183 7.K. Janssen van Doorn, M. Heylen, T. Mets, D. Verbeelen. Evaluation of functional and mental state and Quality of Life in chronic haemodialysis patients. Int Urol Nephrol 2004; 36(2): 263\_267 8.K. Janssen van Doorn, D. Pierard, H. Spapen. Acute renal dysfunction in Salmonella gastroenteritis. J Clin Gastroenterol 2006;40(10):910\_912 9.K. Janssen van Doorn, M. Diltoer and H. Spapen. Do\_Not\_Resuscitate orders in the critically\_ill patient. An observational study with special emphasis on withholding of renal replacement therapy. Acta Clin Belg. 2008;63:221\_6. 10.K. Janssen van Doorn, H. Spapen, C. Geers, M. Diltoer and W Shabana. Sepsis\_related acute kidney injury: a protective effect of drotrecogin alfa (activated) treatment? Acta Anaesthesiol Scand 2008; 52(9): 1259\_64. 11.K. Janssen van Doorn. Intensieve Geneeskunde \_therapeutisch beleid of therapeutische hardnekkigheid? NTT 2009; 63(2):43\_54. 12.J. Verheyen, T. Vermeulen, K. Janssen van Doorn, C. Vrints, V. Conraads. Treating humo\_ral rejection after cardiac transplantation. Acta Cardiologica 2011;66(2):

263. 266 13.H.D. Spapen, K. Janssen van Doorn, M. Diltoer, W. Verbrugghe, R. Jacobs, N. Dobbeleir, P.M. Honoré, P.G. Jorens. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. *Annals Intensive Care* 2011, 1:26-35. K. Janssen van Doorn. Levenskunst en hoop, twee revitaliserende factoren. *Filosofie & Praktijk* 2011; 32(3): 36-47. 16.H. Spapen, K. Janssen van Doorn. Pulmonary septic shock with or without concomitant acute kidney injury. Does activated protein C make a difference? *Crit Care & Shock* 2011; 14(3): 60-64. 17.C. Van Noten, K. Janssen van Doorn, E. Vermander, S. Vlayen, G.A. Verpooten, M.M. Couttenye. Maximal conservative therapy of calcific uremic arteriolopathy. *Clin Nephrol* 2012;(78):61-63. 18.S. Vellinga, W. Verbrugghe, R. De Paep, G.A. Verpooten, K. Janssen van Doorn. Identification of Modifiable Risk Factors for Acute Kidney Injury after Cardiac Surgery. *Neth J Med* 2012;70(10):450-4. 19.K. Janssen van Doorn, E. Dirinck, G.A.Verpooten, M.M. Couttenye. Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. *Clinical Kidney Journal* 2013;6:216-219. 20.E. Philipse, V. Van Marck, G.A. Verpooten, K. Janssen van Doorn. A patient with oliguria and hemoptysis: do not forget the lung-kidney connection! *Internal and Emergency Medicine*. 2013: may 4. 21.S. Vellinga, G.A. Verpooten, K. Janssen van Doorn. Trends in therapeutic plasma exchange; a single-center evaluation. *Int J Artif Organs* 2013 Nov 20;36(10):730-7. 22. A. Verlinden, A. Van de Velde, G.A. Verpooten, K. Janssen van Doorn. Determining factors predictive of CD34+cell collection efficiency in an effort to avoid extended and repeated apheresis sessions. *J Clin Apher.* 2013 Aug 24. 23.Karin Janssen van Doorn, Walter Verbrugghe, Kristien Wouters, Hilde Jansens, Philippe G Jorens. The duration of hypotension determines the evolution of bacteremia-induced acute kidney injury in the intensive care unit. *PLOS ONE* 2014 12;9 (12) 24. Karin Janssen van Doorn. Sepsis induced acute kidney injury still remains a challenge. *EMJ* 2017.

### Projects

Co-investigator in following clinical trials: Omapatrilat versus amlodipine in essential hypertension VALUE Erythropoietine B: RecoJet® versus conventional needle CREATE: Recopen IMPACT: Sirolimus versus Cyclosporine in renal transplantation CERLO80: Myfortic versus Cellcept in renal transplantation SHARF: intermittent versus continuous dialysis in acute renal failure (multi-center study) NAVIGATOR Linezolid M/1260/0080: Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the treatment of catheter-related gram-positive bloodstream infections (multi-center study) APSEP: Safety and effect of Calf Intestinal Alkaline Phosphatase in patients with sepsis WELPICUS PRIMIS: Pharmaco-epidemiology Registry Protocol. STABILO ML21348 MILESTONE: Mid dilution International prospective Study ON outcome. CAN\_004/CANVAS TRIAL: Autologous Dendritic Cells as Treatment in Patients with epithelial ovarian cancer. SOTIO\_DCVAC/Pca in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1stLine Chemotherapy. Principal investigator in following clinical trials: LMW-heparin versus unfractionated heparin in continuous hemodialysis (single-center study) Drotrecogin (Xigris) versus unfractionated heparin in continuous hemodialysis (single-center study) Cognitive functioning disturbing in hemodialysis patients (single-center study)

### Memberships

Member editorial board: 'Tijdschrift voor gezondheidszorg en ethiek'

### Other Relevant Information